AC Immune FY2024 EPS Forecast Increased by Leerink Partnrs

AC Immune SA (NASDAQ:ACIU) – Stock analysts at Leerink Partnrs upped their FY2024 earnings per share estimates for AC Immune in a report issued on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman now expects that the company will earn ($0.57) per share for the year, up from their previous estimate of ($0.60). The consensus estimate for AC Immune’s current full-year earnings is ($0.63) per share. Leerink Partnrs also issued estimates for AC Immune’s Q4 2024 earnings at ($0.19) EPS, FY2025 earnings at ($0.83) EPS and FY2026 earnings at ($0.55) EPS.

Separately, HC Wainwright restated a “buy” rating and set a $16.00 price objective on shares of AC Immune in a research report on Friday, November 15th.

AC Immune Trading Up 2.3 %

ACIU opened at $2.70 on Friday. The company has a 50 day moving average of $2.89 and a 200 day moving average of $3.19. AC Immune has a 12 month low of $2.25 and a 12 month high of $4.98. The company has a market cap of $267.14 million, a PE ratio of -5.87 and a beta of 1.29.

Institutional Trading of AC Immune

Several hedge funds have recently made changes to their positions in the business. Cubist Systematic Strategies LLC purchased a new stake in shares of AC Immune during the 2nd quarter worth $218,000. China Universal Asset Management Co. Ltd. raised its holdings in AC Immune by 63.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 19,021 shares of the company’s stock worth $72,000 after purchasing an additional 7,400 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of AC Immune by 6.4% during the third quarter. Geode Capital Management LLC now owns 58,296 shares of the company’s stock valued at $220,000 after buying an additional 3,499 shares during the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.